98 related articles for article (PubMed ID: 16413634)
1. Partial and full agonism in endomorphin derivatives: comparison by null and operational model.
Rónai AZ; Al-Khrasani M; Benyhe S; Lengyel I; Kocsis L; Orosz G; Tóth G; Kató E; Tóthfalusi L
Peptides; 2006 Jun; 27(6):1507-13. PubMed ID: 16413634
[TBL] [Abstract][Full Text] [Related]
2. Receptor constants for endomorphin-1 and endomorphin-1-ol indicate differences in efficacy and receptor occupancy.
Al-Khrasani M; Orosz G; Kocsis L; Farkas V; Magyar A; Lengyel I; Benyhe S; Borsodi A; Rónai AZ
Eur J Pharmacol; 2001 Jun; 421(1):61-7. PubMed ID: 11408050
[TBL] [Abstract][Full Text] [Related]
3. A Tyr-W-MIF-1 analog containing D-Pro2 discriminates among antinociception in mice mediated by different classes of mu-opioid receptors.
Nakayama D; Watanabe C; Watanabe H; Mizoguchi H; Sakurada T; Sakurada S
Eur J Pharmacol; 2007 Jun; 563(1-3):109-16. PubMed ID: 17343845
[TBL] [Abstract][Full Text] [Related]
4. Novel approach to demonstrate high efficacy of mu opioids in the rat vas deferens: a simple model of predictive value.
Riba P; Friedmann T; Király KP; Al-Khrasani M; Sobor M; Asim MF; Spetea M; Schmidhammer H; Furst S
Brain Res Bull; 2010 Jan; 81(1):178-84. PubMed ID: 19800397
[TBL] [Abstract][Full Text] [Related]
5. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
6. A Tyr-W-MIF-1 analog containing D-Pro2 acts as a selective mu2-opioid receptor antagonist in the mouse.
Watanabe H; Nakayama D; Ito K; Watanabe C; Mizoguchi H; Fujimura T; Murayama K; Kawamura S; Sato T; Sakurada C; Sakurada T; Sakurada S
J Pharmacol Exp Ther; 2005 Mar; 312(3):1075-81. PubMed ID: 15561796
[TBL] [Abstract][Full Text] [Related]
7. Potent morphiceptin analogs: structure activity relationships and morphine-like activities.
Chang KJ; Wei ET; Killian A; Chang JK
J Pharmacol Exp Ther; 1983 Nov; 227(2):403-8. PubMed ID: 6313901
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
[TBL] [Abstract][Full Text] [Related]
9. Endomorphin-2: a biased agonist at the μ-opioid receptor.
Rivero G; Llorente J; McPherson J; Cooke A; Mundell SJ; McArdle CA; Rosethorne EM; Charlton SJ; Krasel C; Bailey CP; Henderson G; Kelly E
Mol Pharmacol; 2012 Aug; 82(2):178-88. PubMed ID: 22553358
[TBL] [Abstract][Full Text] [Related]
10. Novel endomorphin-2 analogs with mu-opioid receptor antagonist activity.
Kruszynski R; Fichna J; do-Rego JC; Chung NN; Schiller PW; Kosson P; Costentin J; Janecka A
J Pept Res; 2005 Sep; 66(3):125-31. PubMed ID: 16083439
[TBL] [Abstract][Full Text] [Related]
11. Activation and internalization of the mu-opioid receptor by the newly discovered endogenous agonists, endomorphin-1 and endomorphin-2.
McConalogue K; Grady EF; Minnis J; Balestra B; Tonini M; Brecha NC; Bunnett NW; Sternini C
Neuroscience; 1999 Mar; 90(3):1051-9. PubMed ID: 10218804
[TBL] [Abstract][Full Text] [Related]
12. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
[TBL] [Abstract][Full Text] [Related]
13. Ligand-selective activation of mu-oid receptor: demonstrated with deletion and single amino acid mutations of third intracellular loop domain.
Chaipatikul V; Loh HH; Law PY
J Pharmacol Exp Ther; 2003 Jun; 305(3):909-18. PubMed ID: 12626655
[TBL] [Abstract][Full Text] [Related]
14. Tetrapeptide Endomorphin Analogs Require Both Full Length and Truncated Splice Variants of the Mu Opioid Receptor Gene Oprm1 for Analgesia.
Marrone GF; Lu Z; Rossi G; Narayan A; Hunkele A; Marx S; Xu J; Pintar J; Majumdar S; Pan YX; Pasternak GW
ACS Chem Neurosci; 2016 Dec; 7(12):1717-1727. PubMed ID: 27648914
[TBL] [Abstract][Full Text] [Related]
15. Biased Agonism of Endogenous Opioid Peptides at the μ-Opioid Receptor.
Thompson GL; Lane JR; Coudrat T; Sexton PM; Christopoulos A; Canals M
Mol Pharmacol; 2015 Aug; 88(2):335-46. PubMed ID: 26013541
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain.
Goldberg IE; Rossi GC; Letchworth SR; Mathis JP; Ryan-Moro J; Leventhal L; Su W; Emmel D; Bolan EA; Pasternak GW
J Pharmacol Exp Ther; 1998 Aug; 286(2):1007-13. PubMed ID: 9694962
[TBL] [Abstract][Full Text] [Related]
17. Endomorphin-1 and endomorphin-2 show differences in their activation of mu opioid receptor-regulated G proteins in supraspinal antinociception in mice.
Sánchez-Blázquez P; Rodríguez-Díaz M; DeAntonio I; Garzón J
J Pharmacol Exp Ther; 1999 Oct; 291(1):12-8. PubMed ID: 10490881
[TBL] [Abstract][Full Text] [Related]
18. Opioid antagonist properties of the highly delta-receptor-selective BOC-Tyr-Pro-Gly-Phe-Leu-Thr (OtBu) peptide and of its Phe1 and Mel1 analogues.
Rónai AZ; Magyar A; Orosz G; Borsodi A; Benyhe S; Tóth G; Makó E; Kátay E; Babka E; Medzihradszky K
Arch Int Pharmacodyn Ther; 1995; 330(3):361-9. PubMed ID: 8836454
[TBL] [Abstract][Full Text] [Related]
19. Behavioral effects of opioid peptides selective for mu or delta receptors. I. Morphine-like discriminative stimulus effects.
Locke KW; Holtzman SG
J Pharmacol Exp Ther; 1986 Sep; 238(3):990-6. PubMed ID: 3018230
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
